FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891864941> ?p ?o ?g. }

• W2891864941 endingPage "2506" @default.
• W2891864941 startingPage "2496" @default.
• W2891864941 abstract "Adoptive T cell therapy has had dramatic successes in the treatment of virus-related malignancies and infections following hematopoietic stem cell transplantation. We adapted this method to produce ex vivo expanded HIV-specific T cells (HXTCs), with the long-term goal of using HXTCs as part of strategies to clear persistent HIV infection. In this phase 1 proof-of-concept study (NCT02208167), we administered HXTCs to antiretroviral therapy (ART)-suppressed, HIV-infected participants. Participants received two infusions of 2 × 107 cells/m2 HXTCs at a 2-week interval. Leukapheresis was performed at baseline and 12 weeks post-infusion to measure the frequency of resting cell infection by the quantitative viral outgrowth assay (QVOA). Overall, participants tolerated HXTCs, with only grade 1 adverse events (AEs) related to HXTCs. Two of six participants exhibited a detectable increase in CD8 T cell-mediated antiviral activity following the two infusions in some, but not all, assays. As expected, however, in the absence of a latency reversing agent, no meaningful decline in the frequency of resting CD4 T cell infection was detected. HXTC therapy in ART-suppressed, HIV-infected individuals appears safe and well tolerated, without any clinical signs of immune activation, likely due to the low residual HIV antigen burden present during ART. Adoptive T cell therapy has had dramatic successes in the treatment of virus-related malignancies and infections following hematopoietic stem cell transplantation. We adapted this method to produce ex vivo expanded HIV-specific T cells (HXTCs), with the long-term goal of using HXTCs as part of strategies to clear persistent HIV infection. In this phase 1 proof-of-concept study (NCT02208167), we administered HXTCs to antiretroviral therapy (ART)-suppressed, HIV-infected participants. Participants received two infusions of 2 × 107 cells/m2 HXTCs at a 2-week interval. Leukapheresis was performed at baseline and 12 weeks post-infusion to measure the frequency of resting cell infection by the quantitative viral outgrowth assay (QVOA). Overall, participants tolerated HXTCs, with only grade 1 adverse events (AEs) related to HXTCs. Two of six participants exhibited a detectable increase in CD8 T cell-mediated antiviral activity following the two infusions in some, but not all, assays. As expected, however, in the absence of a latency reversing agent, no meaningful decline in the frequency of resting CD4 T cell infection was detected. HXTC therapy in ART-suppressed, HIV-infected individuals appears safe and well tolerated, without any clinical signs of immune activation, likely due to the low residual HIV antigen burden present during ART." @default.
• W2891864941 created "2018-09-27" @default.
• W2891864941 creator A5001652365 @default.
• W2891864941 creator A5007455653 @default.
• W2891864941 creator A5008716404 @default.
• W2891864941 creator A5016464841 @default.
• W2891864941 creator A5017003043 @default.
• W2891864941 creator A5022220685 @default.
• W2891864941 creator A5024560316 @default.
• W2891864941 creator A5033471393 @default.
• W2891864941 creator A5033997937 @default.
• W2891864941 creator A5049794472 @default.
• W2891864941 creator A5057326864 @default.
• W2891864941 creator A5066139971 @default.
• W2891864941 creator A5067715206 @default.
• W2891864941 creator A5073909182 @default.
• W2891864941 creator A5091054721 @default.
• W2891864941 date "2018-10-01" @default.
• W2891864941 modified "2023-10-02" @default.
• W2891864941 title "HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals" @default.
• W2891864941 cites W1555983429 @default.
• W2891864941 cites W1589352827 @default.
• W2891864941 cites W1914813822 @default.
• W2891864941 cites W1927667480 @default.
• W2891864941 cites W1928021774 @default.
• W2891864941 cites W1963802821 @default.
• W2891864941 cites W1967714946 @default.
• W2891864941 cites W1967794036 @default.
• W2891864941 cites W1983062149 @default.
• W2891864941 cites W1996210947 @default.
• W2891864941 cites W2004709238 @default.
• W2891864941 cites W2005407342 @default.
• W2891864941 cites W2007607803 @default.
• W2891864941 cites W2008966955 @default.
• W2891864941 cites W2011626958 @default.
• W2891864941 cites W2019904910 @default.
• W2891864941 cites W2026547100 @default.
• W2891864941 cites W2029307020 @default.
• W2891864941 cites W2030844138 @default.
• W2891864941 cites W203198182 @default.
• W2891864941 cites W2040400654 @default.
• W2891864941 cites W2047012867 @default.
• W2891864941 cites W2051879794 @default.
• W2891864941 cites W2055796578 @default.
• W2891864941 cites W2060055494 @default.
• W2891864941 cites W2060829964 @default.
• W2891864941 cites W2061687066 @default.
• W2891864941 cites W2066666411 @default.
• W2891864941 cites W2070740443 @default.
• W2891864941 cites W2074322976 @default.
• W2891864941 cites W2075106941 @default.
• W2891864941 cites W2075906228 @default.
• W2891864941 cites W2078599357 @default.
• W2891864941 cites W2082871926 @default.
• W2891864941 cites W2085307859 @default.
• W2891864941 cites W2085384576 @default.
• W2891864941 cites W2092524383 @default.
• W2891864941 cites W2101516953 @default.
• W2891864941 cites W2104342628 @default.
• W2891864941 cites W2105323221 @default.
• W2891864941 cites W2105393333 @default.
• W2891864941 cites W2105901192 @default.
• W2891864941 cites W2106051882 @default.
• W2891864941 cites W2106174953 @default.
• W2891864941 cites W2109130469 @default.
• W2891864941 cites W2112072045 @default.
• W2891864941 cites W2117962018 @default.
• W2891864941 cites W2120014878 @default.
• W2891864941 cites W2120020619 @default.
• W2891864941 cites W2142424393 @default.
• W2891864941 cites W2142621481 @default.
• W2891864941 cites W2144227351 @default.
• W2891864941 cites W2144549163 @default.
• W2891864941 cites W2150457116 @default.
• W2891864941 cites W2152534166 @default.
• W2891864941 cites W2153778605 @default.
• W2891864941 cites W2154705046 @default.
• W2891864941 cites W2159215305 @default.
• W2891864941 cites W2161762733 @default.
• W2891864941 cites W2166295153 @default.
• W2891864941 cites W2522854796 @default.
• W2891864941 cites W2593271030 @default.
• W2891864941 cites W2608841238 @default.
• W2891864941 cites W2612307934 @default.
• W2891864941 cites W2735653597 @default.
• W2891864941 cites W2742056095 @default.
• W2891864941 cites W2749571720 @default.
• W2891864941 cites W2757825315 @default.
• W2891864941 cites W2760211048 @default.
• W2891864941 cites W2767134981 @default.
• W2891864941 cites W2774292278 @default.
• W2891864941 cites W2790506421 @default.
• W2891864941 cites W2794490228 @default.
• W2891864941 cites W4233900719 @default.
• W2891864941 doi "https://doi.org/10.1016/j.ymthe.2018.08.015" @default.
• W2891864941 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6171327" @default.
• W2891864941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30249388" @default.
• W2891864941 hasPublicationYear "2018" @default.

• next